Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis,
harnesses the power of the immune system to treat cancer, with unique potential for a …

We report the results of 24 women, 50%(N= 12) with hormone receptor-positive breast
cancer and 50%(N= 12) with advanced triple-negative breast cancer, treated with …

Minimally invasive thermal therapies have been attempted in the treatment of breast cancer,
and the immune response induced by these therapies has not been fully reported. A clinical …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Immunotherapy has become the breakthrough strategies for treatment of cancer in recent
years. The application of messenger RNA in cancer immunotherapy is gaining tremendous …

Triple-negative breast cancer (TNBC) is the most lethal breast cancer subtype owing to the
lack of targeted therapeutic strategies. Immunogenic cell death (ICD), a modality of …

Introduction Immunotherapy has revolutionized cancer treatment, including TNBC, which
has limited options of treatment and poor prognosis. ICIs studied in TNBC include …

Simple Summary In this review, we present current knowledge of sex hormones in the
process of development of malignant diseases. The impact of sex hormones on immune …